All lobbying filings

BAKER & HOSTETLER LLP

BAKER & HOSTETLER LLP filed a Q4 report for FERRING PHARMACEUTICALS, INC. on January 17, 2026, reporting $60,000 in lobbying income.

Lobbying for FERRING PHARMACEUTICALS, INC. · Biopharmaceutical company

All filings by BAKER & HOSTETLER LLP · Everything FERRING PHARMACEUTICALS, INC. has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 17, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Regulatory and reimbursement policy issues related to federal healthcare programs associated with gene therapy, IVF therapy and oncology treatments.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.